J. Buckner

发表

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

E. Shaw, Meihua Wang, S. Coons, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pragmatic study designs for older adults with cancer: Report from the U13 conference.

J. Buckner, K. Ballman, R. Nipp, 2016, Journal of geriatric oncology.

SSBP2 Variants Are Associated with Survival in Glioblastoma Patients

Brooke L. Fridley, Ivan Smirnov, Paul A. Decker, 2012, Clinical Cancer Research.

Management of brain metastases from thyroid carcinoma

J. Buckner, R. McWilliams, J. Atkinson, 2003, Cancer.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

J. Buckner, P. Brown, K. Ballman, 2007, Neuro-oncology.

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Alexander R. Pico, Susan M. Chang, M. Berger, 2015, The New England journal of medicine.

Imaging in Clinical Trials

J. Buckner, B. Erickson, 2007, Cancer informatics.

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas

J. Buckner, B. Erickson, P. Korfiatis, 2016, Medical physics.

Factors influencing survival in high-grade gliomas.

Jan C Buckner, J. Buckner, 2003, Seminars in oncology.

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Walter J. Curran, Mark R. Gilbert, Jean-Paul Bahary, 2016, The New England journal of medicine.

Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.

J. Buckner, J. Lewis, E. A. McElroy, 1998, Neurosurgery.

Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade

B. Scheithauer, J. O'fallon, R. Dinapoli, 2007, Journal of Neuro-Oncology.

Melanoma-induced brain metastases

J. Buckner, P. Brown, R. McWilliams, 2008, Expert review of anticancer therapy.

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

B. Scheithauer, J. Buckner, E. Galanis, 2008, Journal of Neuro-Oncology.

Brain metastatic lesions.

E. Shaw, B. O'neill, R. Dinapoli, 1994, Mayo Clinic proceedings.

Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402.

B. Scheithauer, E. Shaw, W. Curran, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.

Maria Werner-Wasik, Lucia Zamorano, Walter J Curran, 2004, International journal of radiation oncology, biology, physics.

In reply to Dr. Kondziolka et al

P. Okunieff, W. Curran, D. Brachman, 2005 .

In response to Drs. Vordermark and Kölbl

P. Okunieff, W. Curran, D. Brachman, 2005 .

Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma

J. Uhm, J. Buckner, F. Meyer, 2012, Journal of Neuro-Oncology.

Irinotecan in the treatment of glioma patients

J. O'fallon, J. Buckner, C. Erlichman, 2003, Cancer.

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Susan M. Chang, W. Yung, M. Prados, 2014, Neuro-oncology.

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Leland S. Hu, J. Sarkaria, J. Buckner, 2018, Neuro-oncology.

Chemotherapy, irradiation, and surgery for function‐preserving therapy of primary extremity soft tissue sarcomas

F. Sim, J. Buckner, M. Mahoney, 2002, Cancer.

Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.

T. Cascino, J. Buckner, J. Ingle, 1999, Neurosurgery.

Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.

T. Cascino, J. Buckner, R. Marks, 1998, International journal of radiation oncology, biology, physics.

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.

E. Perez, J. Buckner, D. Sargent, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cerebral blood volume and apparent diffusion coefficient – Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma

J. Buckner, B. Erickson, P. Korfiatis, 2019, Journal of the Neurological Sciences.

Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.

B. Scheithauer, E. Shaw, W. Curran, 2010, International journal of radiation oncology, biology, physics.

QOL and Survival Comparisons by Race in Oncology Clinical Trials.

J. Buckner, J. Sloan, P. Novotny, 2016, Journal of cancer and clinical oncology.

Chemotherapy for Advanced CNS Ependymoma

B. Scheithauer, J. Buckner, B. Erickson, 2004, Journal of Neuro-Oncology.

NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.

J. Buckner, D. Sargent, H. McLeod, 2009, The oncologist.

Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients.

J. Buckner, P. Brown, M. Clark, 2007, Journal of pain and symptom management.

Innovation in the management of brain metastases.

J. Buckner, P. Brown, R. Rao, 2007, Oncology.

Treatment options for brain metastases from melanoma

J. Buckner, P. Brown, R. McWilliams, 2005, Expert review of anticancer therapy.

Treatment of brain metastases from melanoma.

J. Buckner, P. Brown, R. McWilliams, 2003, Mayo Clinic proceedings.

Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

H. Cohen, J. Buckner, J. Mandelblatt, 2020, Journal of geriatric oncology.

Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.

J. Buckner, D. Sargent, R. Goldberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Seizures in patients with primary brain tumors: what is their psychosocial impact?

J. Uhm, J. Buckner, A. Jatoi, 2016, Journal of Neuro-Oncology.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

J. Buckner, D. Sargent, S. Hillman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.

J. Buckner, A. Asher, C. Ménard, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma.

J. Uhm, B. Scheithauer, J. O'fallon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model

J. Sarkaria, J. Buckner, K. Ballman, 2009, Journal of Neuro-Oncology.

N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis

J. Buckner, M. Hidalgo, E. Galanis, 2005 .

Phase I trial of erlotinib with radiation therapy (RT) in patients with glioblastoma multiforme (GBM)

J. Uhm, J. Buckner, P. Brown, 2005 .

Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance

Caterina Giannini, Alfred Furth, Karla Ballman, 2004, Journal of neuropathology and experimental neurology.

Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma

J. Uhm, B. Scheithauer, J. O'fallon, 2004 .

What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

J. Buckner, D. Sargent, S. Mandrekar, 2008 .

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

J. Sarkaria, J. Uhm, J. Buckner, 2010, Clinical Cancer Research.

Cancer esearch cer Therapy : Clinical bination of Temsirolimus ( CCI-779 ) with Chemoradiation ewly Diagnosed Glioblastoma Multiforme ( GBM ) CTG trial N 027 D ) Is Associated with R eased Infectious Risks

J. Uhm, J. Buckner, P. Brown, 2010 .

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.

B. Scheithauer, J. O'fallon, T. Cascino, 2001, Cancer.

Management of recurrent meningeal hemangiopericytoma

B. Scheithauer, J. Buckner, E. Galanis, 1998, Cancer.

Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials.

J. Buckner, D. Sargent, E. Galanis, 2012 .

Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice.

J. Buckner, J. Sloan, A. Grothey, 2014, Journal of oncology practice.

Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation.

J. Olson, C. James, B. Scheithauer, 1999, International journal of oncology.

Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.

J. O'fallon, R. Dinapoli, T. Cascino, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic signi cance of an apoptotic index and apoptosis / proliferation ratio for patients with high-grade astrocytomas 1

B. Scheithauer, J. O'fallon, J. Buckner, 2005 .

Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas.

B. Scheithauer, J. O'fallon, J. Buckner, 2002, Neuro-oncology.

Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility

Alexander R. Pico, Ivan Smirnov, Paul A. Decker, 2009, Nature Genetics.

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

J. Buckner, P. Wen, N. Butowski, 2022, Neuro-oncology advances.

Triple-dose Contrast/magnetization Transfer Suppressed Imaging of ‘non-enhancing’ Brain Gliomas

J. O'fallon, B. O'neill, J. Buckner, 2002, Journal of Neuro-Oncology.

Long-term Outcomes and Role of Chemotherapy in Adults With Newly Diagnosed Medulloblastoma

J. Buckner, F. Rodriguez, Wenting Wu, 2014, American journal of clinical oncology.

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

J. Buckner, M. Hidalgo, A. Berkenblit, 2010, Investigational New Drugs.

Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.

J. Buckner, E. Korn, G. Hortobagyi, 2013, Journal of the National Cancer Institute.

A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology

Jeffery T. Sloan, J. Buckner, A. Dispenzieri, 2022, Contemporary clinical trials communications.

A Randomized Trial of Cyclophosphamide, Doxorubicin, and Prednisone Versus Cyclophosphamide, 5‐Fluorouracil, and Prednisone in Patients with Metastatic Breast Cancer

D. Schaid, J. Buckner, J. Ingle, 1991, American journal of clinical oncology.

A Randomized Phase II and Pharmacokinetic Study of Dacarbazine in Patients with Recurrent Glioma

B. Scheithauer, J. Buckner, S. Vincent Rajkumar, 2000, Journal of Neuro-Oncology.

Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize.

J. Buckner, E. Galanis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

J. Uhm, R. Arusell, J. Buckner, 2010, Journal of Neuro-Oncology.

The role of chemotherapy in the treatment of patients with brain metastases from solid tumors

J. Buckner, 1991, Cancer and Metastasis Reviews.

Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials.

K. Aldape, C. James, B. Scheithauer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas

J. Buckner, R. Marks, M. Mahoney, 2002, Cancer investigation.

North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.

J. Sarkaria, J. Uhm, J. Buckner, 2011, International journal of radiation oncology, biology, physics.

NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients 1

J. Sarkaria, J. Uhm, J. Buckner, 2011 .

Thromboembolism in patients with high-grade glioma.

J. O'fallon, R. Dinapoli, J. Buckner, 1994, Mayo Clinic proceedings.

Chemotherapy of brain tumors

J. Buckner, E. Galanis, 2000, Current opinion in neurology.

Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma

B. Scheithauer, J. O'fallon, T. Cascino, 2004, Journal of Neuro-Oncology.

Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors.

J. O'fallon, E. Shaw, J. Buckner, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)

J. Buckner, D. Moore, E. Galanis, 2007 .

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial.

J. Buckner, P. Brown, C. Hadjipanayis, 2022, JAMA oncology.

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.

J. Buckner, P. Brown, A. Asher, 2017, International journal of radiation oncology, biology, physics.

ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG).

E. Shaw, W. Curran, S. Coons, 2015 .

AT-13R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE

E. Shaw, W. Curran, S. Coons, 2014 .

Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.

E. Shaw, W. Curran, S. Coons, 2014 .

Brain metastases from colorectal carcinoma: The long term survivors

T. Cascino, J. Buckner, M. O’connell, 1996, Cancer.

Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG)

E. Shaw, Meihua Wang, D. Brachman, 2008 .

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.

J. Sarkaria, B. Scheithauer, J. Buckner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma

J. Buckner, K. Olsen, T. Moynihan, 2005, Journal of Neuro-Oncology.

Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG).

E. Shaw, S. Coons, D. Brachman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.

J. O'fallon, R. Dinapoli, J. Earle, 2002, International journal of radiation oncology, biology, physics.

Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.

B. Scheithauer, R. Dinapoli, J. Buckner, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.

R. Dinapoli, T. Cascino, J. Buckner, 1998, International journal of radiation oncology, biology, physics.

Clinical Trials with Interferon-Alpha as a Chemosensitizer in Gliomas

J. Buckner, 1996 .

Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor

B. Scheithauer, J. O'fallon, T. Cascino, 1996, Journal of Neuro-Oncology.

Impact of adjuvant temozolomide and IDH mutation status among patients with anaplastic astrocytoma.

J. Uhm, J. Buckner, P. Decker, 2013 .

Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.

J. Sarkaria, J. Buckner, R. Rao, 2004, Current cancer drug targets.

Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency.

J. Buckner, J. Edmonson, T. Fitch, 1989, Journal of the National Cancer Institute.

Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392).

J. Buckner, J. Sloan, S. Mandrekar, 2012 .

Phase II evaluation of carboplatin in advanced endometrial carcinoma.

J. Buckner, J. Edmonson, H. Wieand, 1988, Journal of the National Cancer Institute.

Current issues in diagnosis and treatment of primary and metastatic brain tumors.

J. Buckner, 2004, Seminars in oncology.

Phase I Study of Difluoromethylornithine in Combination with Recombinant α2a-Interferon

J. Buckner, J. Kovach, L. Kvols, 1988 .

Effective chemotherapy for advanced CNS embryonal tumors in adults.

B. Scheithauer, J. Buckner, E. Galanis, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An evaluation of recombinant leukocyte a interferon with aspirin in patients with metastatic renal cell cancer

D. Schaid, J. Buckner, J. Kovach, 1988, Cancer.

Surgery, radiation therapy, and chemotherapy for metastatic tumors to the brain

J. Buckner, 1992, Current opinion in oncology.

NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

J. Uhm, J. Buckner, E. Galanis, 2010 .

Phase I Trial of Combined Recombinant Interleukin‐2 with Levamisole in Patients with Advanced Malignant Disease

J. Buckner, J. Katzmann, E. Creagan, 1994, American journal of clinical oncology.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas

B. Scheithauer, T. Cascino, J. Buckner, 2000, Investigational New Drugs.

Management of Malignant Pineal Germ Cell Tumors with Residual Mature Teratoma

B. Scheithauer, J. Buckner, C. Raffel, 2001, Neurosurgery.

Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma.

J. Buckner, P. Brown, C. Wetmore, 2010, International journal of radiation oncology, biology, physics.

Cisplatin-based chemotherapy in primary central nervous system germ cell tumors

B. Scheithauer, J. Buckner, Shreyaskumar R Patel, 2004, Journal of Neuro-Oncology.

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

J. Buckner, S. Vuk-Pavlović, M. Peshwa, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

M. Prados, T. Cascino, W. Curran, 2004, International journal of radiation oncology, biology, physics.

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

C. James, B. Scheithauer, J. O'fallon, 2001, Journal of the National Cancer Institute.

Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas.

C. James, B. Scheithauer, J. O'fallon, 1998, International journal of oncology.

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Li Zhang, Howard Colman, Dima Suki, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

J. Uhm, J. Buckner, E. Galanis, 2013, Clinical Cancer Research.

GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.

Susan M. Chang, J. Buckner, D. Bigner, 2005, Neuro-oncology.

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Caterina Giannini, Walter J Curran, Jan C Buckner, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.

Kathleen R. Lamborn, Jan C. Buckner, Michael D. Prados, 2010, Neuro-oncology.

Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma

M. Prados, J. Buckner, P. Novotny, 2007 .

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Caterina Giannini, Jan C Buckner, B. Scheithauer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?

Jennifer S. Yu, J. Buckner, D. Cahill, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

Caterina Giannini, Howard Gross, Chunrong Yu, 2012, Neuro-oncology.

Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy

Wei Zhang, D. Brat, J. Buckner, 2015, Proceedings of the National Academy of Sciences.

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

E. Shaw, R. Arusell, J. Buckner, 2006, Cancer research.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Susan M. Chang, D. Brat, J. Sarkaria, 2019, Neuro-oncology.

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis

R. B. Jenkins, B. Scheithauer, J. Buckner, 2011, Journal of Neuro-Oncology.

Management of low-grade glioma: a systematic review and meta-analysis.

M. Berger, J. Buckner, P. Brown, 2018, Neuro-oncology practice.

Management of diffuse low-grade gliomas in adults — use of molecular diagnostics

J. Buckner, J. Eckel-Passow, R. Jenkins, 2017, Nature Reviews Neurology.

Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development

J. Buckner, S. Kizilbash, M. Ruff, 2020, Expert review of anticancer therapy.

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

E. Shaw, W. Curran, Meihua Wang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conditional probability of long‐term survival in glioblastoma

J. Buckner, J. Hammack, D. Ma, 2012, Cancer.

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.

K. Aldape, E. Shaw, D. Brachman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-grade and anaplastic oligodendroglioma.

J. Buckner, M. J. van den Bent, J. Bromberg, 2016, Handbook of clinical neurology.

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Caterina Giannini, Jan C Buckner, Paul D Brown, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spindle cell rhabdomyosarcoma of bone with FUS–TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype

Asha A. Nair, J. Buckner, A. Folpe, 2018, Histopathology.

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Walter Curran, Luis Souhami, B. Scheithauer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading

B. Scheithauer, J. Buckner, A. Weaver, 2001, Journal of neuropathology and experimental neurology.

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

T. Cascino, J. Buckner, D. Macdonald, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

J. Buckner, M. Hidalgo, C. Erlichman, 2006, Clinical Cancer Research.

Pharmacokinetic Study ofTemsirolimus ( CCI-779 ) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

J. Buckner, M. Hidalgo, C. Erlichman, 2006 .

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

J. Sarkaria, J. Uhm, J. Buckner, 2015, Neuro-oncology.

High‐dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system

J. Buckner, E. Galanis, T. Christianson, 2008, Cancer.

Phase II trial of gemcitabine in advanced sarcomas

J. Buckner, E. Galanis, M. Mahoney, 2002, Cancer.

A phase III study of radiation therapy plus carmustine with or without recombinant interferon‐α in the treatment of patients with newly diagnosed high‐grade glioma

B. Scheithauer, J. O'fallon, T. Cascino, 2001 .

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

B. Scheithauer, J. Buckner, M. Hidalgo, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Manual of Clinical Problems in Oncology: With Annotated Key References

J. Buckner, 1987 .

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.

R. McLendon, D. Brat, J. Buckner, 2015, Archives of pathology & laboratory medicine.

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

C. James, J. Uhm, B. Scheithauer, 2011, International journal of radiation oncology, biology, physics.

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

J. Uhm, J. Buckner, P. Brown, 2006, International journal of radiation oncology, biology, physics.

Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.

Bradley J Erickson, Jan C Buckner, J. Buckner, 2006, Neuro-oncology.

40 – Esthesioneuroblastoma: Management and outcome

J. Buckner, K. Olsen, E. Moore, 2012 .

Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial.

B. Scheithauer, J. O'fallon, E. Shaw, 2004, International journal of radiation oncology, biology, physics.

A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872

J. Buckner, D. Tran, D. Schiff, 2019, Cancer.

Glioblastoma: Biology, diagnosis, and treatment

J. Buckner, M. Mrugala, Akanksha Sharma, 2018 .

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma

J. Buckner, L. Hartmann, G. Wiseman, 1995, Cancer.

Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination.

B. Scheithauer, J. O'fallon, E. Shaw, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

J. Buckner, P. Brown, C. Hadjipanayis, 2017, The Lancet. Oncology.

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Volker W Stieber, Cynthia Ménard, Jan C Buckner, 2016, JAMA.

Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas

R. Arusell, J. Buckner, P. Brown, 2006, Journal of Neuro-Oncology.

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3).

J. Buckner, P. Brown, C. Hadjipanayis, 2019, International journal of radiation oncology, biology, physics.

Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study.

B. Scheithauer, E. Shaw, W. Curran, 2012 .

Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.

E. Shaw, B. O'neill, W. Curran, 2020, Neuro-oncology.

Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.

E. Shaw, D. Brachman, J. Buckner, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Central neurocytoma: management recommendations based on a 35-year experience.

B. Scheithauer, J. Buckner, P. Brown, 2007, International journal of radiation oncology, biology, physics.

Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.

J. Buckner, P. Brown, K. Ballman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival

R. Arusell, J. Buckner, P. Brown, 2005, Neurosurgery.

Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma.

B. Scheithauer, J. O'fallon, E. Shaw, 2004, International journal of radiation oncology, biology, physics.

Choroid Plexus Papillomas: A Single Institutional Experience

B. Scheithauer, J. Buckner, P. Brown, 2004, Journal of Neuro-Oncology.

Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas.

J. O'fallon, R. Dinapoli, J. Buckner, 2000, Journal of neurosurgery.

Does histologic grade in soft tissue sarcoma influence response rate to systemic chemotherapy?

D. Schaid, J. Buckner, J. Edmonson, 1991, Cancer.

"I think it's been met with a shrug:" Oncologists' views toward and experiences with Right-to-Try.

J. Buckner, J. Tilburt, A. Adjei, 2020, Journal of the National Cancer Institute.

Long-Term Outcome of Esthesioneuroblastoma: Hyams Grade Predicts Patient Survival

J. Buckner, J. V. Van Gompel, K. Olsen, 2012, Journal of Neurological Surgery—Part B.

Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon.

J. Buckner, J. Kovach, L. Kvols, 1988, Cancer research.

Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas.

D. Schaid, J. Buckner, C. Loprinzi, 1989, Journal of the National Cancer Institute.

Complications of Therapy

J. Buckner, P. Brown, J. Ashman, 2011 .

Malignant primary cardiac tumors

Jan C Buckner, Hartzell V Schaff, J. Buckner, 2008, Cancer.

Central nervous system tumors.

Jan C Buckner, Paul D Brown, J. Uhm, 2007, Mayo Clinic proceedings.

A Prospective Study of Quality of Life in Adults With Newly Diagnosed High-Grade Gliomas: Comparison of Patient and Caregiver Ratings of Quality of Life

R. Arusell, J. Buckner, P. Brown, 2008, American journal of clinical oncology.

2 Variants Are Associatedwith Survival in Glioblastoma Patients

Susan M. Chang, M. Berger, J. Olson, 2012 .

Word Count : 3425 Number of Tables : 3 Number of Figures : 3 Statement of Translational Relevance : Glioblastoma

Susan M. Chang, M. Berger, J. Olson, 2012 .

Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial.

E. Shaw, S. Coons, D. Brachman, 2008, Journal of neurosurgery.

Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow up in 38 patients.

B. Scheithauer, J. Buckner, W. Marsh, 2003, Journal of neurosurgery.

Residual Deep Convolutional Neural Network Predicts MGMT Methylation Status

Bradley J. Erickson, Panagiotis Korfiatis, Timothy L. Kline, 2017, Journal of Digital Imaging.

Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51.

E. Shaw, R. Arusell, W. Curran, 2011, International journal of radiation oncology, biology, physics.

Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.

J. Buckner, K. Ballman, R. Jenkins, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials.

E. Shaw, Meihua Wang, J. Buckner, 2013, Neuro-oncology.

Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.

E. Shaw, R. Arusell, R. Ivnik, 2005, International journal of radiation oncology, biology, physics.

A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation

Alexander R. Pico, Susan M. Chang, M. Berger, 2012, Nature Genetics.

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma

Jesse S. Voss, J. Uhm, J. Buckner, 2014, Journal of Neuro-Oncology.

Phase II study of amonafide in patients with recurrent glioma

Jan C. Buckner, B. Scheithauer, J. O'fallon, 2005, Journal of Neuro-Oncology.

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma

B. O'neill, J. Buckner, A. Dietz, 2022, Neuro-oncology advances.

The neurocognitive effects of radiation in adult low-grade glioma patients.

J. Uhm, E. Shaw, J. Buckner, 2003, Neuro-oncology.

N107C/CEC.3: A Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

J. Buckner, P. Brown, C. Hadjipanayis, 2016 .

Randomized, Placebo-Controlled, Phase III Surgical Adjuvant Clinical Trial of Megestrol Acetate (Megace) in Selected Patients With Malignant Melanoma

R. Fitzgibbons, J. Buckner, J. Krook, 2002, American journal of clinical oncology.

Effects o f R adiotherapy o n C ognitive F unction i n P atients With L ow-Grade G lioma M easured b y t he F olstein Mini-Mental S tate E xamination

B. Scheithauer, E. Shaw, R. Arusell, 2003 .

Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.

J. Buckner, P. Brown, C. Giannini, 2013, Neuro-oncology.

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma

J. Buckner, K. Ballman, K. Jaeckle, 2009, Neurology.

A phase II study of recombinant human alpha‐interferon in advanced hormone‐refractory prostate cancer

J. Buckner, L. Kvols, R. Hahn, 1992, Cancer.

Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?

J. Sarkaria, J. Buckner, N. Laack, 2015, Seminars in radiation oncology.

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients

T. Cascino, J. Buckner, H. Sandler, 2006, Journal of Neuro-Oncology.

Temozolomide induced bone marrow Suppression–A single institution outcome analysis and review of the literature

J. Buckner, T. Kourelis, N. Gangat, 2015, American journal of hematology.

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02

B. Scheithauer, E. Shaw, W. Curran, 2004 .

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

B. Scheithauer, J. O'fallon, T. Cascino, 1995, Journal of neurosurgery.

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

E. Shaw, B. O'neill, W. Curran, 2015, Neuro-oncology practice.

Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.

B. Scheithauer, J. O'fallon, R. Dinapoli, 1998, Journal of neurosurgery.

QLIF-08. DETERMINING THE NET CLINICAL BENEFIT IN NEURO-ONCOLOGY CLINICAL TRIALS BY COMBINING SURVIVAL AND TOXICITY DATA

J. Buckner, J. Sloan, B. Major, 2017 .

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

J. Sarkaria, J. Buckner, P. Brown, 2019, Journal of Neuro-Oncology.

Chemotherapy for high-grade gliomas

J. Buckner, E. Galanis, 2000, British Journal of Cancer.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

M. Prados, C. Miller, J. Sarkaria, 2018, Neuro-oncology.

Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients.

J. Uhm, J. Buckner, F. Meyer, 2013, Journal of neurosurgery.

Controversies in the Therapy of Low-Grade Gliomas

J. Buckner, I. Carabenciov, 2019, Current Treatment Options in Oncology.

Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.

J. Buckner, M. J. van den Bent, M. Geurts, 2018, Neuro-oncology practice.

The use of PCV chemotherapy in oligodendrogliomas

J. Buckner, M. Ruff, 2019, Oligodendroglioma.

Adjuvant nitrosoureas: will they ever go away?

J. Buckner, 2017, Neuro-oncology.

A Randomized Trial of Chemotherapy Plus Radiotherapy (RT) versus RT alone for Anaplastic Oligodendroglioma (RTOG 9402): The Perspective of Longer Follow-up

Susan M. Chang, B. Scheithauer, E. Shaw, 2008 .

Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma

B. Scheithauer, J. O'fallon, T. Cascino, 1991, Journal of Neuro-Oncology.

Unusual presentation of adult metastatic peritoneal medulloblastoma associated with a ventriculoperitoneal shunt: a case study and review of the literature.

J. Buckner, W. Cliby, R. Rao, 2003, Neuro-oncology.

COMP-05. EVALUATION OF A DEEP LEARNING ARCHITECTURE FOR MRI PREDICTION OF IDH, 1p19q AND TERT IN GLIOMA PATIENTS

Jennie W. Taylor, J. Buckner, B. Erickson, 2018, Neuro-Oncology.

Impact of imaging measurements on response assessment in glioblastoma clinical trials.

Susan M. Chang, J. Buckner, D. Reardon, 2014, Neuro-oncology.

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.

B. Scheithauer, J. O'fallon, E. Shaw, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.

B. Scheithauer, J. O'fallon, R. Arusell, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02.

B. Scheithauer, E. Shaw, W. Curran, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression

Bradley J Erickson, Rickey E Carter, Zachary S Kelm, 2015, Journal of medical imaging.

Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma.

B. Scheithauer, J. O'fallon, T. Cascino, 1990, Journal of neuro-oncology.

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

J. Buckner, M. Dhodapkar, H. Pitot, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Temozolomide: too early for definitive conclusions.

J. Buckner, P. Brown, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spinal intradural extraosseous Ewing's sarcoma

J. Buckner, A. Bardia, A. Nassar, 2011, Rare tumors.

The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma

J. Buckner, P. Brown, C. Kreofsky, 2017, Journal of Neuro-Oncology.

Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors

B. Scheithauer, J. Buckner, J. Krook, 1999, Cancer.

North Central Cancer Treatment Group--achievements and perspectives.

E. Perez, J. Buckner, D. Sargent, 2008, Seminars in oncology.

Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.

Susan M. Chang, W. Curran, J. Buckner, 2004, International journal of radiation oncology, biology, physics.

Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.

B. Scheithauer, J. O'fallon, R. Dinapoli, 2005, International journal of radiation oncology, biology, physics.

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial

Matthew J. Maurer, Jan C. Buckner, B. Scheithauer, 2005, Investigational New Drugs.

Primary neuroendocrine carcinoma of the brain

J. Buckner, T. Halfdanarson, N. Duma, 2019, BMJ Case Reports.

Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients.

J. Buckner, D. Sargent, J. Sloan, 2015, SOJ anesthesiology & pain management.

Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales

J. Buckner, J. Singh, J. Sloan, 2014, Health and Quality of Life Outcomes.

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

T. Cascino, J. Buckner, Wenting Wu, 2011, Neuro-oncology.

Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

J. Buckner, J. Tilburt, A. Adjei, 2021, PloS one.

Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking.

Faith Davis, Yuanyuan Xiao, Brooke L Fridley, 2011, American journal of epidemiology.

Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.

Jan C Buckner, Bernd W Scheithauer, B. Scheithauer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

J. Sarkaria, J. Buckner, B. Erickson, 2018, Cancer.

Cancer Therapy : Clinical Phase II StudyofBevacizumab inCombinationwithSorafenib in Recurrent Glioblastoma ( N 0776 ) : A North Central Cancer Treatment Group Trial

J. Uhm, J. Buckner, E. Galanis, 2013 .

A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.

M. Prados, T. Cascino, W. Curran, 1999, International journal of radiation oncology, biology, physics.

NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM)

J. Buckner, M. Hidalgo, E. Galanis, 2004 .

Quantification of the impact of enzyme‐inducing antiepileptic drugs on irinotecan pharmacokinetics and SN‐38 exposure

J. Buckner, E. Galanis, J. Reid, 2015, Journal of clinical pharmacology.

NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).

J. Buckner, M. Hidalgo, E. Galanis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer

J. O'fallon, J. Buckner, J. Ingle, 1989, Breast Cancer Research and Treatment.

ACTR-37. PREDICTIVE SIGNIFICANCE OF IDH1/2 MUTATION AND 1p/19q CO-DELETION STATUS IN A POST-HOC ANALYSIS OF NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS

K. Aldape, E. Shaw, S. Coons, 2017 .

5‐Fluorouracil Plus Leucovorin in Women with Metastatic Breast Cancer A Phase II Study

D. Schaid, J. Buckner, J. Ingle, 1991, American journal of clinical oncology.

A patient-level meta-analytic investigation of the prognostic significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials

J. Buckner, J. Sloan, P. Novotny, 2008 .

Gut microbiota differs significantly between men with and without prostate cancer

J. Buckner, 2022, Cancer.

NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM).

J. Buckner, D. Tran, D. Schiff, 2015 .

Gliomatosis cerebri: clinical characteristics, management, and outcomes

Jonathan M. Morris, J. Buckner, D. Lachance, 2013, Journal of Neuro-Oncology.

Efficacy of Antineoplastons A10 and AS2-1: In Response

J. Buckner, M. Malkin, J. Reid, 1999 .

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.

T. Cascino, J. Buckner, M. Malkin, 1999, Mayo Clinic proceedings.

Analysis of paired glioma tissues from initial diagnosis and recurrence in patients enrolled on NCCTG clinical trials: De-differentiation and association with survival.

B. Scheithauer, J. Buckner, K. Ballman, 2006, Journal of Clinical Oncology.

Evaluation of Menogaril in Patients with Metastatic Sarcomas and No Prior Chemotherapy Exposure

D. Schaid, J. Buckner, J. Ingle, 1989, American journal of clinical oncology.

Phase I study of combined alpha Interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy

J. Buckner, V. Ganju, J. Edmonson, 2004, Investigational New Drugs.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD)

J. Buckner, D. Petereit, E. Basch, 2021, Cancer.

Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.

J. Buckner, J. Singh, J. Sloan, 2014 .

Optimizing Whole Brain Radiotherapy Dose and Fractionation: Results from a Prospective Phase III Trial (NCCTG N107C (Alliance)/CEC.3)

J. Buckner, P. Brown, E. Galanis, 2019, International Journal of Radiation Oncology*Biology*Physics.

BMET-05NCCTG N0574 (ALLIANCE): A PHASE III RANDOMIZED TRIAL OF WHOLE BRAIN RADIATION THERAPY (WBRT) IN ADDITION TO RADIOSURGERY (SRS) IN PATIENTS WITH 1 TO 3 BRAIN METASTASES

J. Buckner, P. Brown, A. Asher, 2015 .

ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA

Leland S. Hu, J. Sarkaria, J. Uhm, 2018, Neuro-Oncology.

CNS Malignancies: At Last, Real Progress

J. Buckner, T. Lawrence, F. Lang, 2006 .

The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD

J. Buckner, D. Petereit, E. Basch, 2018, BMC Cancer.

Optimal radiotherapy target volumes in intracranial nongerminomatous germ cell tumors: Long‐term institutional experience with chemotherapy, surgery, and dose‐ and field‐adapted radiotherapy

J. Buckner, D.J. Daniels, M. Blanchard, 2017, Pediatric blood & cancer.

Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials

J. Buckner, P. Flynn, M. Kosel, 2008 .

Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): report of RTOG 93-05 protocol

P. Okunieff, W. Curran, D. Brachman, 2002 .

Phase II evaluation of menogaril in patients with advanced hypernephroma

T. Therneau, J. Buckner, R. Hahn, 1991, Investigational New Drugs.

NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.

J. Buckner, D. Sargent, H. McLeod, 2009, The oncologist.

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

J. Uhm, J. Buckner, E. Galanis, 2013, Clinical Cancer Research.

Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression

Zachary S. Kelm, Zachary S Kelm, J. Buckner, 2015, Journal of medical imaging.

Choroid Plexus Papillomas: A Single Institutional Experience

B. Scheithauer, J. Buckner, P. Brown, 2004, Journal of Neuro-Oncology.

Validation of single item Linear Analogue Scale Assessments (LASAs) for assessing quality of life (QOL) in patients with newly diagnosed high-grade gliomas.

J. Buckner, P. Brown, M. Clark, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial.

E. Perez, J. Buckner, D. Sargent, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor

J. Buckner, N. Wetjen, L. Eckel, 2014, Journal of Neuro-Oncology.